Is bradycardia safe while taking Dayvigo (lemborexant) in a 37-year-old patient with insomnia?

A heart rate of 58 bpm in a 37-year-old patient taking Dayvigo is generally safe and does not require discontinuation of the medication.

Assessment of the Clinical Scenario

The heart rate of 58 bpm represents mild sinus bradycardia but is not inherently dangerous in this context. According to the 2018 ACC/AHA/HRS bradycardia guidelines, the critical first step is determining whether this bradycardia is symptomatic and whether it's related to a reversible cause 1. In this case, you need to evaluate:

• Is the patient symptomatic? Look specifically for:

  • Syncope or presyncope episodes
  • Lightheadedness or dizziness
  • Fatigue beyond what's expected from insomnia alone
  • Chest pain or dyspnea

• Is Dayvigo the cause? Review the timeline: Did bradycardia develop after starting Dayvigo, or was it pre-existing?

Dayvigo Safety Profile and Cardiac Effects

Importantly, bradycardia is not listed as a recognized adverse effect of Dayvigo (lemborexant) in the FDA labeling 2. The most common adverse reactions reported in clinical trials were:

• Somnolence (10% for 10mg, 7% for 5mg)
• Headache (5.9% for 10mg, 4.5% for 5mg)
• Nightmares/abnormal dreams (2.2%)

The only cardiovascular-related adverse event mentioned was palpitations, which led to discontinuation in 0.6% of patients on the 10mg dose 2. There were no reports of bradycardia or heart rate reduction in the phase 3 trials involving 1,418 patients 2.

Clinical Decision Algorithm

If the patient is asymptomatic:

• Continue Dayvigo without modification
• A heart rate of 58 bpm in a young adult without symptoms does not meet criteria for intervention per bradycardia guidelines 1
• Many healthy adults, particularly those who are physically active, have resting heart rates in the 50s

If the patient is symptomatic:

• First, determine if symptoms correlate temporally with the bradycardia (use ambulatory monitoring if needed) 1
• If symptoms occur without documented bradycardia, the heart rate is not the culprit
• If symptoms correlate with bradycardia, evaluate for reversible causes before attributing to Dayvigo:
  • Other medications (beta-blockers, calcium channel blockers, digoxin, antiarrhythmics)
  • Hypothyroidism
  • Electrolyte abnormalities (hypokalemia, severe acidosis)
  • Sleep apnea 1

Given that bradycardia is not a known Dayvigo side effect, if symptomatic bradycardia is present, investigate other causes first rather than immediately discontinuing the insomnia medication.

Important Caveats

• The 2018 bradycardia guidelines explicitly state that permanent pacing should not be performed for asymptomatic bradycardia, even with documented sinus node dysfunction 1
• At age 37, this patient is far from the typical elderly population where bradycardia becomes more clinically significant
• Dayvigo has demonstrated efficacy and safety in clinical trials lasting up to 12 months, with no cardiac safety signals emerging 3, 4
• The drug's mechanism (dual orexin receptor antagonism) does not involve cardiac conduction pathways, making bradycardia mechanistically unlikely

Monitoring Recommendations

Continue Dayvigo and monitor for:

• Development of symptoms (dizziness, syncope, fatigue)
• Further heart rate decline below 50 bpm
• Any new medications that could contribute to bradycardia

The combination of a 58 bpm heart rate and Dayvigo use does not constitute a contraindication or safety concern requiring medication discontinuation in this 37-year-old patient.